ModraDoc006/r in Patients With Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

A Multicentre Phase IIa Study to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Patients With Recurrent or Metastatic HER-2 Negative Breast Cancer, Suitable for Treatment With a Taxane

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03890744
• Other study ID #: M18DMB
• Status: Completed
• Phase: Phase 2
• Start date: January 30, 2019
• Est. completion date: November 9, 2020

Study information

• Verified date: March 2019
• Source: Modra Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter phase IIa study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with recurrent or metastatic HER-2 negative breast cancer, that are suitable for treatment with a taxane as 1st-3rd line of therapy.

Description:

This is a phase IIa, multicentre, two-stage, single-arm, clinical study with the primary objective is to determine the efficacy of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with recurrent or metastatic HER-2 negative breast cancer, as measured by RECIST v1.1 criteria of objective response rate (ORR). To this aim, a Simon two-stage minimax design will be used, in which 14 evaluable patients will be treated in the first stage (Stage A). If 0 or ≥ 2 objective responses at week 8 (with confirmation at week 12) are observed in Stage A, no further patients will be enrolled. If 1 objective response is observed, an additional 10 patients with recurrent or metastatic HER-2 negative breast cancer will be included in the second stage (Stage B).

All patients will be treated with ModraDoc006/r, given as oral tablets twice daily once weekly (BIDW).

Patients will be radiologically assessed at week 8 and 12 by CT scan (or MRI if CT is contraindicated), and may continue to receive study medication with ongoing radiological scans every 6 weeks until disease progression (according to RECIST v1.1), unacceptable toxicity, or discontinuation for any other reason.

Furthermore, the safety and tolerability of ModraDoc006/r in the target population will be assessed. Additionally, as metastatic breast cancer may occur at older age, often coinciding with other non-malignant diseases and co-medications, this protocol investigates whether ModraDoc006/r can be applied safely in these (frail) patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: November 9, 2020
• Est. primary completion date: February 13, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to give written informed consent and to comply with the protocol

2. Histologically- or cytologically confirmed diagnosis of recurrent or metastatic HER-2 negative breast cancer

3. Female of age 18 years or above

4. Patients who are eligible to receive a taxane as monotherapy as 1st-3rd line of therapy for recurrent or metastatic breast cancer. A maximum of two previous lines of chemotherapy is allowed (including experimental i.e. non-registered chemotherapy alone or in combination). Re-treatment with one of the same drugs after treatment interruption for reasons of patient preference and/or progression of disease counts as a new treatment

5. WHO performance status of 0, 1 or 2 (Appendix II)

6. Estimated life expectancy of at least 12 weeks

7. Resolution of toxicity of prior therapy to < grade 2 (except for alopecia and transaminases in case of liver metastases) as defined by CTCAE v5.0 (Appendix III)

8. Evidence of measurable disease present at baseline as defined by RECIST v1.1

9. Able and willing to swallow oral medication

10. Able and willing to undergo radiologic scans (CT scan, or MRI if CT is contraindicated)

11. All patients of childbearing potential must have a negative high sensitive pregnancy test at screening (urine/serum) and agree to use highly effective method for contraception from time of signing Informed Consent until at least 12 weeks after the last administration of study drug

12. Laboratory criteria:

• Platelet count = 100 x 109 /L

• Haemoglobin = 6.0 mmol/L or 9.67 g/dL

• Absolute Neutrophil Count (ANC) = 1.5 x 109 /L

• Total bilirubin = 1.5 x ULN, except for patients with familial bilirubinaemia (Gilbert's disease)

• Serum ASAT and ALAT = 2.5 x ULN (= 5 x ULN with liver metastases)

• Serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min (by Cockcroft-Gault formula or MDRD [Modification of Diet in Renal Disease])

Exclusion Criteria:

1. Systemic chemotherapy or radiation therapy within the last 4 weeks, endocrine based therapy and CDK4/6 inhibitors within 1 week prior to first dose of ModraDoc006/r. Single dose palliative radiation for pain relieve is allowed until one week prior to start with ModraDoc006/r (these lesions are not to be included as target lesions)

2. Any treatment with investigational drugs (or investigational device) within 21 days prior to receiving the first dose of ModraDoc006/r

3. Previous treatment with a taxane for recurrent or metastatic breast cancer

4. Major surgical procedures within 21 days prior to providing informed consent

5. Active acute or chronic infection, which is not controlled by appropriate medication (at the discretion of the treating physician)

6. Uncontrolled or significant cardiovascular disease defined as New York Heart Association Classification III or IV

7. Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the Investigator would impair study compliance

8. Any medical condition that in the opinion of the Investigator would contra-indicate or preclude participation within the clinical trial, or would put the patient at high risk for treatment-related complications

9. Previous malignancies within the last three years other than breast carcinoma, except successfully treated squamous/basal cell carcinoma of the skin, superficial bladder cancer, and in situ carcinoma of the cervix

10. Patients with symptomatic brain metastases. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy for at least 6 weeks are allowed to enrol. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening, demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive anti-epileptic drugs or corticosteroid treatment indicated for brain metastasis

11. Patients with confirmed leptomeningeal metastases

12. Women who are pregnant or breast feeding

13. Known positivity for Human Immunodeficiency Virus HIV-1 or HIV-2 type

14. Patients with known active infection of hepatitis B, C, or E (patients who are anti-HBC positive but HBsAg negative are eligible to participate in this study)

15. Bowel obstructions or motility disorders that may influence the resorption of drugs as judged by the Investigator

16. Patients with unstable ascites, defined as need for palliative paracentesis or presence of a permanent peritoneal drain in the past 4 weeks prior to first dose of ModraDoc006/r. Enrolment in patients with peritonitis carcinomatosa and malignant ascites is allowed if there is no clinical and/or radiological known or suspected motility disorder within the 4 weeks prior to the first dose of ModraDoc006/r

17. Concomitant use of MDR, MRP, OATP1B1, OATP1B3 and CYP3A modulating drugs such as Ca+- entry blockers (verapamil, dihydropyridines), cyclosporine, quinidine, and grapefruit juice, concomitant use of HIV medications, other protease inhibitors, (non) nucleoside analogues, or St. John's wort (see section 5.8). These need to have been stopped at least 5 times the terminal half-life (according to Summary of Product Characteristics (SPC)) or 7 days, whichever is longest, in order to prevent interaction with the drug. Tamoxifen and megestrol need to be stopped only 1 week prior to start of the first dose of ModraDoc006/r

18. Legal incapacity

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer
• Recurrent Breast Cancer

Intervention

Drug:
• ModraDoc006/r
Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets

Locations

Country	Name	City	State
Belgium	Institut Jules Bordet	Brussels
Belgium	Centre Hospitalier Universitaire de Liège	Liège
Denmark	Odense University Hospital	Odense
Spain	Hospital Quiron Pozuelo	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Modra Pharmaceuticals

Countries where clinical trial is conducted

Belgium,  Denmark,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The number of CTCAE v.4.03 toxicities during treatment with ModraDoc006/r in a population of frail patients	The hematological and non-hematological toxicity profile of ModraDoc006/r in frail patients will be assessed by clinical and lab evaluation and evaluated according to CTCAE v.4.03	Evaluation of toxicities during the complete study treatment until 28 days after the last intake, using the CTCAEv4.03 grading system
Primary	The objective response rate (ORR)	Evaluation of objective response rate that will be observed as measured by RECIST v1.1 criteria, in patients with recurrent or metastatic HER2 negative breast cancer after treatment with ModraDoc006/r	From baseline through study completion, an average of 1 year
Secondary	The number of CTCAE v.4.03 toxicities during treatment with ModraDoc006/r	The hematological and non-hematological toxicity profile of ModraDoc006/r will be assessed by clinical and lab evaluation and evaluated according to CTCAE v.4.03	Evaluation of toxicities during the complete study treatment until 28 days after the last intake, using the CTCAEv4.03 grading system
Secondary	The activity data on progression-free survival (PFS) of ModraDoc006/r	Evaluation of progression free interval (PFS) that will be observed as measured by RECIST v1.1 criteria, in patients with recurrent or metastatic HER2 negative breast cancer during and after treatment with ModraDoc006/r	From baseline through study completion, an average of 1 year